EGFR and non-small cell lung carcinoma: Certain molecular features of NSCLC, e.g., epidermal growth factor receptor (EGFR) mutations, modulate the risk of brain metastases, while also representing targets for primary systemic therapy (Andratschke et al. 2019; Wang et al. 2021).